tbuckley/cabot-search huggingface dataset:
Abstract 1785: Renal Artery Angioplasty Improves Diastolic Cardiac Function In Patients With heart failure Possessing Renal Artery Stenosis.
Authors: Eisei Yamamoto, Hitoshi Takano, Hiroyuki Tajima, Jun Tanabe, Hidekazu Kawanaka, Shuhei Tara, Yasuhiro Takahashi, Nobuhiko Fujita, Gen Takagi, Satoshi Aoki, Kuniya Asai, Masahiro Yasutake, Morimasa Takayama, Kyoichi Mizuno
Journal: Circulation (2007)

Background: Renal artery stenosis (RAS) often plays an important role not only in malignant hypertension but also in sudden development of heart failure (HF) so called ‘flash pulmonary edema’ or chronic HF refractory to medical treatment. One of the possible mechanisms whereby RAS affects these unique conditions of HF is suppression of LV compliance through the complex interaction between neurohormonal systems originating from the reduction of renal blood flow. Renal artery angioplasty is expected to be an effective treatment for restoring renal blood flow in patients with RAS. The aim of the present study was whether the angioplasty can improve the impaired neurohormonal systems and diastolic cardiac function in patients with RAS. Methods: A prospective analysis was performed in 18 HF patients with RAS (age: 72±6, 3 females, NYHA I/II/III: 5/9/4) who underwent renal artery angioplasty between 2005 and 2007. Four patients with significant bilateral RAS and 3 patients with unilateral RAS in the vessel supplying a functional solitary kidney were included. We monitored the changes of biochemical and neurohormonal markers and blood pressure. Cardiac function was evaluated by tissue Doppler echocardiogram before and 3 months after the procedure. Results: Technical success was achieved in all interventions. The results are shown in table . Systolic arterial blood pressure significantly decreased by renal angioplasty. B-type natriuretic peptide (BNP) was significantly reduced 3 months after the angioplasty, whereas the change of sCr or angiotensinII was not statistically significant. Myocardial early diastolic velocity (Em), a parameter of diastolic LV function, was significantly improved compared with that measured before the procedure. Conclusions: In patients with either overt or latent HF possessing RAS, renal artery angioplasty not only decreases arterial blood pressure but also improves diastolic cardiac function in parallel with the reduction of BNP level.
Water and Water Supplies.
Authors: Thresh, Thomas Sterry Hunt, John Clough, John C. Thresh
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study
Authors: Hagop M. Kantarjian, Ghulam J. Mufti, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Anne Meibohm, Angela Lopez, Aristoteles Giagounidis
Journal: Blood (2013)
Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients
Authors: Holly Lynn Geyer, Robyn M Scherber, Amylou Constance Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stephanie Slot, Sonja Zweegman, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Dohner, Claire N. Harrison, Deepti H Radia, Pablo J. Muxi, Federico Sackman, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Gunnar Birgegard, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman I Maldonado, Giovanni Barosi, Maria Ferrari, Keith Cannon, Peter te Boekhorst, Harry C Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Ruben Mesa
Journal: Blood (2014)
Das Hormon der Herzbewegung.
Authors: Ludwig. Haberlandt
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5147: A Cluster Randomised Controlled Trial to Evaluate an Ambulatory Primary Care Management Program for Patients with Dyslipidemia: TEAM Study
Authors: Julie Villeneuve, Jacques Genest, Marc Fredette, Lucie Blais, Djamal Berbiche, Diane Lamarre, Marie-Thérèse Lussier, Marie-Claude Vanier, Eveline Hudon, Lyne Lalonde
Journal: Circulation (2008)

Dyslipidemia management in primary care is often sub-optimal. New Quebec (Canada) legislation increases the potential for family physician-community pharmacist collaborative care (PPCC). We hypothesized that PPCC can improve the management of dyslipidemia. In a randomized controlled trial, clusters of physicians and pharmacists within the same geographical area were randomly assigned to the PPCC or the usual care (UC) group. PPCC pharmacists attended a one-day workshop and successfully completed a clinical skills evaluation. In the PPCC intervention, the physicians are responsible for the diagnosis and the prescription of lipid-lowering pharmacotherapy, while the pharmacists initiate treatment; request appropriate laboratory tests; monitor effectiveness, safety, and adherence to treatment; and adjust medication dosage accordingly. In PPCC, physician-pharmacist communication procedures were pre defined to enhance professional collaboration. Moderate and high CHD risk patients initiating statin treatment or currently on treatment but inadequately controlled were recruited and followed-up for 1 year. The primary endpoint was the mean change difference in LDL between groups after 1 year. Secondary endpoints included the proportion of patients at or below their target LDL and TC/HDL ratio, as defined by the Canadian Lipid Guidelines, after 1 year. Multilevel and multivariate regression models were used. We enrolled 15 clusters of physicians and pharmacists (PPCC: 108 patients; UC: 117 patients). The mean change in LDL after 1 year was -1.11 mmol/L (95%CI: −1.26 to −0.96) and −0.89 mmol/L (−0.95 to −0.83) in PPCC and UC groups, respectively. The adjusted mean change difference in LDL between PPCC and UC groups was −0.11 mmol/L (−0.34 to 0.11). After 1 year, 80.6% of PPCC patients and 72.9% of UC patients were at or below their target lipid levels (adjusted OR 2.1; 1.2 to 3.8; p=0.008). PPCC patients had more lipid-lowering pharmacotherapy changes (OR: 2.0; 1.1 to 3.8) and were more likely to report lifestyle changes (OR: 3.9; 2.4 to 6.3). Our data shows that the Family physician-community pharmacist collaborative care improves the adherence to the Canadian Lipid Guidelines.( ISRCTN66345533 )
Prognostic value of the expression of <i>tumor necrosis factor-alpha</i> (TNFa) and its receptors in head and neck cancer (HNC) patients: A pilot study
Authors: F. Clatot, J. Picquenot, M. Cornic, H. Hamidou, I. Tennevet, O. Choussy, A. François, L. Hong, S. Laberge-Le- Couteulx, E. Blot
Journal: Journal of Clinical Oncology (2009)

e17029 Background: TNFa was initially described as an inductor of apoptosis in cancer cells. In vitro data showed that TNFa can also activate anti-apoptotic signaling in cancer cells. We analyzed the prognostic value of the expression of TNFa and its receptors TNFR1 and TNFR2 in HNC patients. Methods: Twenty-four patients treated for HNC were retrospectively analyzed for TNFa, TNFR1, and TNFR2 expression by real-time PCR (RT-PCR). Tissue samples were collected at the time of initial diagnosis. Total RNA was reverse-transcribed with TaqMan quantitative RT-PCR (Applied Biosystems). Results were recorded as average threshold cycle, and relative expression was determined using Normalized Expressions method. Expression of TNFa, TNFR1, and TNFR2 was related to survival after 3 years of follow-up. Results: In the 24 patients, expression of TNFa (mean value 7.8, median 2.4, range 0.02–62.3), TNFR1 (mean value 58, median 49, range 0.02–246.9) and TNFR2 (mean value 4.8, median 3.3, range 0.8–18.9) demonstrated a great variability between patients. After a 3-year follow-up, 14 patients were alive without evolution of cancer (group A) and 10 were dead because of cancer evolution (group D). In group D, median level of TNFa was 8.8 whereas it was 1.1 in group A (p = 0.02). Median level of TNFR1 was 71.8 in group D and 28.5 in group A (p = 0.01). In contrast, median level of TNFR2 was 3.3 for both groups. Patients with high level of TNFa or TNFR1 expression had a worse survival (p = 0.01 and p = 0.009, respectively). There was also a strong correlation between high expression of TNFa and of TNFR1 (p = 0.0007). Conclusions: In this small series, TNFa and TNFR1 expression seem to have significant prognostic value to predict survival of HNC patients. This result needs to be confirmed in larger series and compared with usual prognostic factor. It suggests that TNFa expression could have a dual effect in HNC and that TNFR1 expression may play a role in this process. No significant financial relationships to disclose.
Contraception: Science and Practice
Authors: Marcus Filshie, John Guillebaud
Journal: Annals of Internal Medicine (1989)

Birth control - a world view, M.Potts and P.Bhiwandiwala metabolic effects of combined oral contraceptives, M.D.G.Gillmer complications of combined oral contraception, J.Drife oral contraception and cancer, M.P.Vessey practical prescribing of the combined oral contraceptive pill, J.Guillebaud the progestogen-only pill, K.Fotherby systemic hormonal contraception by non-oral routes, I.S.Fraser postcoital contraception, A.Yuzpe and A.Kubba intrauterine contraceptive devices, H.JTatum and kE.B.Connell male and female barrier contraceptive methods, Walli Bounds natural family planning, Anna M.Flynn and J.Bonnar contraception for the older woman, P.Bowen-Simpkins cervical ripening prior to termination of pregnancy, G.M.Filshie et al abortion, G.M.Filshie female sterilization and it reversal, J.E.Rioux vasectomy and vasectomy reversal, W.F.Hendry progress towards a systematic male contraceptive, S.L.Jeffcoate.
Better outcome after 2 years with an early invasive strategy in unstable coronary artery disease (UCAD) - FRISCII 2 year follow-up.
Authors: B Lagerqvist, S Husted, F Kontny, E Stahle, Eva Swahn, L Wallentin
Journal: Circulation (2001)

Better outcome after 2 years with an early invasive strategy in unstable coronary artery disease (UCAD) - FRISCII 2 year follow-up.
A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
Authors: D. S. Miller, J. A. Blessing, C. N. Krasner, R. D. Drake, R. Higgins, D. S. McMeekin, L. V. Puneky
Journal: Journal of Clinical Oncology (2009)

e16507 Background: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the endometrium that failed on higher priority treatment protocols and to determine the nature and degree of toxicity. Methods: A multicenter phase II trial was conducted by the Gynecologic Oncology Group (GOG). Patients must have had advanced or recurrent measurable carcinoma of the endometrium and failed one prior chemotherapy regimen. Pemetrexed at a dose of 900 mg/m 2 was to be administered as an IV infusion over 10 minutes every 21 days. Results: From May 1, 2006 to July 31, 2007, 27 patients were entered by ten member institutions of the GOG. A total of 101 cycles were administered with 27% of patients receiving five or more cycles. The treatment was well tolerated overall. More serious toxicities (grade 3 and 4) included anemia in 19%, leukopenia in 38%, neutropenia in 46%, and constitutional in 19%. No treatment related deaths were reported. One patient (4%) had a partial response. Twelve patients (46%) had stable disease and eleven (46%) patients had increasing disease. Median progression-free survival (PFS) was 2.7 months and overall survival (OS) was 9.4 months. Conclusions: Pemetrexed has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested. [Table: see text]
Impact of intensive chemotherapy versus supportive care on quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML)
Authors: M. Leach, S. M. H. Alibhai, M. D. Minden, V. Gupta, A. Schattner, H. Kermalli
Journal: Journal of Clinical Oncology (2005)

8187 Background: Older patients with AML often have a poor prognosis and often do not tolerate intensive chemotherapy. When weighing alternate management strategies (e.g. best supportive care), impact upon QOL should be evaluated. However, there is limited published research in this area. Methods: Patients aged 60 or older presenting with newly diagnosed AML to an AML referral centre were enrolled regardless of treatment intent. Patients were excluded if life expectancy was under 1 month or they did not speak English. QOL was measured at baseline and at 1, 4, and 6 months. Questionnaires included the European Organization for the Research and Treatment of Cancer QLQ-C30 (global health, 5 QOL domains, 3 symptom domains) and the Functional Assessment of Cancer Therapy Fatigue subscale. Patients were stratified by intensive versus non-intensive treatment. Results: From June 2003 to July 2004, 28 patients (mean age 72) were enrolled. At baseline, global health, role function, and social function were the most affected domains. Fatigue was the predominant symptom. Among patients treated intensively, global health, role function, and social function improved over time. Other domains were unchanged. Non-intensively managed patients had smaller improvements in global health and improved role function and cognitive function. Social function declined and other domains remained stable. Fatigue scores improved minimally over time in both groups, and were unaffected by remission status. Pain scores were low at baseline but worsened slightly over time in both groups. Conclusion: QOL in older patients appears to be significantly affected by AML. Intensive chemotherapy is associated with greater improvement or less decline in several domains of QOL but little improvement in fatigue. These results can inform decision-making for older adults with AML and suggest the need for better symptom management. No significant financial relationships to disclose.
A new treatment combining valproate acid (VA) plus doxorubicin (D) for patients with refractory or recurrent malignant mesothelioma (MM): a phase II study
Authors: Arnaud Scherpereel, Thierry Berghmans, Lucas Willems, Marianne Paesmans, Bachar Chahine, Anne-Pascale Meert, Nathalie Leclercq, Fabian Vandermeers, Jean-Jacques Lafitte, Jean-Paul Sculier
Journal: European Respiratory Journal (2009)
Abstract 1592: Statin Therapy Improves Long-Term Outcome in Patients with Reduced Renal Function and Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention
Authors: Michael J Lipinski, Clay A Cauthen, Antonio Abbate, Michael J Cowley, Evelyne Goudreau, George W Vetrovec
Journal: Circulation (2007)

Background. Prior studies have shown that high-risk patients with LV dysfunction had improved survival following PCI when discharged on statin therapy. However, the role of statins in patients with...
Medical Research and Human Welfare. A Record of Personal Experiences and Observations During a Professional Life of Fifty-Seven Years.
Authors: W. W. Keen
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An update on an ongoing measles outbreak in Bulgaria, April-November 2009
Authors: L Marinova, M Muscat, Z Mihneva, M Kojouharova
Journal: Eurosurveillance (2009)

Earlier this year, an outbreak of measles was detected in Bulgaria, following an eight-year period without indigenous measles transmission, and continues to spread in the country. By the end of 48 week of 2009 (first week of November), 957 measles cases had been recorded. Most cases are identified among the Roma community living in the north-eastern part of the country. Measles has affected infants, children and young adults. The vaccination campaign that started earlier in the year in the affected administrative regions continues, targeting all individuals from 13 months to 30 years of age who have not received the complete two-dose regimen of the combined measles-mumps-rubella (MMR) vaccination.
Epidermal growth factor receptor expression correlates with histologic grade but not microsatellite instability in primary colon carcinomas
Authors: R. L. Rego, A. J. French, N. R. Foster, D. J. Sargent, S. R. Alberts, H. Windschitl, M. J. O’Connell, S. N. Thibodeau, F. A. Sinicrope
Journal: Journal of Clinical Oncology (2006)

20023 Background: EGFR is a transmembrane receptor tyrosine kinase belonging to the ErbB family of proteins. Anti-EGFR antibodies have shown efficacy as monotherapy and can enhance cytotoxic chemotherapy in patients with advanced colorectal cancers. We studied EGFR expression in primary colon cancers and its association with, microsatellite instability (MSI), clinicopathological variables and patient survival rates. Methods: Archival colon carcinomas were studied from patients with high risk Dukes’ stage B2 (n = 78) and C (n = 230) patients enrolled in a prior adjuvant trial of 5-fluorouracil, leucovorin plus standard dose or high-dose levamisole (NCCTG 91–46–53). EGFR expression (anti-EGFR H11 antibody, DAKO) was analyzed by immunohistochemistry (IHC) and intensity (0–3+), extent and their product (weighted score) were determined. MSI was analyzed using BAT26 and expression of hMLH1, hMSH2 and hMSH6 proteins by IHC. Patients were censored at 5 years after randomization for DFS and censored at 8 years post study randomization for overall survival (OS) data. Results: EGFR protein expression was detected in 216 of 308 (70%) of Dukes’ B2 and C primary colon carcinomas from patients and localized to the plasma membrane. EGFR expression variables (intensity, extent, weighted score) were increased in poor/undifferentiated compared to moderate/well differentiated tumors (p ≤ 0.036). Similar EGFR expression levels were found in MSI-H (n = 27) versus MSS (n = 203) colon cancers and for other clinicopathological variables. EGFR intensity was more likely moderate (2+) or strong (3+) in Dukes’ C versus B2 tumors (p = 0.088). In addition, higher EGFR intensity (2+, 3+) showed a trend toward worse disease-free survival (5 yr DFS %: 62.2 vs. 71.7; p = 0.095), but not overall survival (p = 0.14). Conclusions: EGFR overexpression is associated with increased tumor aggressiveness as indicated by poor tumor cell differentiation and reduced DFS in colon cancer patients receiving adjuvant 5-FU and levamisole. These findings indicate that EGFR may be an important therapeutic target in the adjuvant setting. [Table: see text]
Coronary angiography in relation to troponin T level in patients with unstable coronary artery disease a FRISC-II substudy.
Authors: B Lagerqvist, E Diderholm, B Lindahl, S Husted, F Kontny, E Stahle, Eva Swahn, P Venge, L Wallentin
Journal: Circulation (2000)

Coronary angiography in relation to troponin T level in patients with unstable coronary artery disease a FRISC-II substudy.